. The tumour concentration for this conipound appeared, however, not to be highly selective: the ratios of the radioactivity concentration in tumour to that in liver or spleen or blood plasma were lower than 0 5. These findings favour the hypothesis (Argus, 1961) that the presence of free acidic groups in the fluorene disulphonamido high molecular compounds contributes to their binding at the cellular adsorption sites by basic proteins.
Compound III is the condensation product of 2,7-fluorene [35S] disulphonylchloride with 2 molecules of urea, thus representing a simple aliphatic side chain and showing a structural resemblance to the previously described bis-guanidyl derivative (Compound II) (Malejka, 1965) . The urea moiety occurs also in Compound IV in which 2 molecules of tolbutamide, (l-butyl-3(p-tolyl-sulphonyl)urea). a hypoglycaemic sulphonamide, have been used to increase the molecular weight of the new compound. Compound V is an analogue of N,N'-bis(p-carboxyphenyl)-4,4'-biphenyl [35S] disulphonamide which in the earlier studies in mice revealed an appreciable concentration in tumour (Argus, Seepe, Gutierrez, Hewson, Rav, 1958) .
Previous studies with the bis-thiazole derivative (Compound I) emphasized the possible meaning of heteroatoms in the thiazole rings, particularly electronegative sulphur for its ability to bind liver and serum proteins and which might influence the affinity of this compound for neoplasms (Kasprzak, Malejka, Gabryel, 1965 Malejka, Kasprzak, Radola, 1966 . These studies were now extended by substituting 2,7-disulphonamido fluorene with groupings containing the somewhat more electronegative nitrogen. Two heterocyclic groupings, 5(6)-nitrobenzimidazolyl and 2,4-dimethoxy-6-amino-pyrimidyl were chosen for this purpose and the respective condensation products are Compounds VI and VII.
MATERIALS AND METHODS

2.7-Fluorene[35S]
disulphonylchloride.-The procedure described previously (Argus and Hewson, 1954) 3.44; N, 13-65; S, 15-63. Found: C, 43-72; H, 3-51; N, 13-33. N,N'-bis(p-tolylsulphonyl-carbamyl-n-butyl)-2,7-fluorene[35S]disulphonamide, N-p-tolylsulphonyl-N-n-butyl-urea (Tolbutamide, U. S. P.), 6.9 g. (0.025 moles) The presence of nitro groups in this compound was proved by their reduction to amino groups, diazotization and coupling with /3-naphtol to give a red dye. The mixture was divided into four 1-2 g. portions. Each portion was introduced into a glass tube, 10 ml. toluene was added and tubes were sealed. Four tubes were placed in an oil bath and temperature was raised up to 180°C. and maintained throughout the following 10 hours. The tubes were allowed to cool to room temperature and opened. The dark beige reaction mass which settled on the tube walls was separated from the toluene solution, and methanol was added (several portions) to help to remove residue from the tubes. Yield of 3-65 g. of crude material was obtained which after drying and powdering in the mortar was extracted with 20 ml. of toluene under refluxing. The material was dried over phosphorus pentoxide. The yield of crude material was 3 g. (91 per cent of theory), carbonizing within the range of 240-300°C. Purification from 20 ml. mixture of N,N-dimethylformamide and dioxane (1: 1) with charcoal and precipitation with methanol gave [1] [2] [3] [4] [5] [6] [7] [8] A total of 52 young male Wistar rats was used; 24 were employed for the subcutaneous transplantation of Walker carcinosarcoma (which was received from Deutsche Akademie der Wissenschaften zu Berlin, Institute fur Medizin und Biologie); 28 tumour-free rats served for the control groups. A week before transplantation, the experimental animals received subcutaneous injections of hydrocortisoneacetate suspension (15 mg. per rat in 3 doses-5 mg. each every second day). When the tumours were 11-20 days old and weighed 3-5-20 g. (in 3 rats metastases were noted after 17 days), the radioactive compounds were administered by tail vein injection. Each rat was given 1-2 ml. 0-05 N NaOH containing 12 mg. C(ompounds III, IV, V, VI or VII. Each animal was then placed in an individual metabolism cage and killed 6 hours following administration of the compounds.
The concentration and per cent recovery of radioactive material in tissues and excreta of rats were determined by methods described previously (Argus, Kane and Ray, 1960; Malejka, 1965 Average value from 2 rats. ** Average value from 3 rats.
could be compared to those for Compounds I and II (Malejka, 1965) , and for other fluorene disulphonamides tested previously (Argus, Kane and Ray, 1960: Malejka, Argus and Ray, 1961 ; Malejka, 1962 (Table II) . This finding together with the per cent in the controls; this is not a significant difference. As the result of the lower values for urine, more Compound IV than III is found in the other tissues and organs of rats. The differences, however, in the distribution of Compound IV between tumour-free and tumour-bearing rats are not statistically significant (Table II) . In tumour, 10 pg. of compound per g. tissue is found; this will be discussed later.
The behaviour of N,N'-bis(4-carboxy-phenyl)-2,7-fluorene[35S]disulphonamide, V, may be compared with the disulphonamides known from the earlier studies. In going from the biphenyl to the fluorene series, the activities of the compounds are not parallel. In the biphenyl series, compound with free carboxylic groups examined in CAF1/Jax mice with a transplanted stomach carcinomata (2 and 8 hours after its administration) showed more selective localization in tumour than the derivative with primary sulphonamido groups (Argus, Seepe, Gutierrez, Hewson, and Ray, 1958) . In the fluorene series, the effect was the opposite: the comparison of Compound V with N,N'-bis(p-sulphamoyl-phenyl)-2,7-fluorene [35S]disulphonamide (Malejka, 1962) (Tables I-A, I-B and Table II ). The excretion of Compound VI into urine remains on a similar level to Compound IV; the concentration of radioactivity in tumour was very much the same.
A portion of the sulphadimethoxine molecule, a sulphonamide known to remain at elevated blood levels for prolonged periods of time, appears in N,N'-bis (6(2,4-dimethoxy-pyrimidyl))-2,7-fluorene[35S]disulphonamide, VII, which similarly to the bis-thiazole derivative, I, (Malejka, 1965 ) is insoluble in water and requires an alkaline pH to dissolve. Compound VII has a higher molecular weight (600.5) than Compound I (490.6). These physico-chemical properties might account for the slow elimination of Compound VII in the rat, and this is slower in the experimental animals than in the controls. In the skin of tumour bearing animals twice as much, and in the small intestines (+ contents) 3 times more, of Compound VII is found as in the controls. (The difference between the two groups of animals for small intestines is at P < 0*001 (t = 7.70). On the other hand, in the large intestines (-+ contents) of tumour-free animals 35 times more and in the urine 2 times more of Compound VII is present than in the tumour-bearing group. The differences in the concentration of Compound VII between the two groups found in the large intestines and in the urine are statistically significant (t = 8X82, P < 0-001 and P _ 0 05 in Table II , respectively).
The response of the reticulo-endothelial system towards the uptake of fluorene disulphonamides is different for every compound presented in this paper. Compound III deviates from the behaviour of four other disulphonamides in that some radioactivity is found in the liver and spleen of tumour-bearers but not in these organs of the control group. This may indicate that only liver impaired by the presence of a tumour in the animal body can take up the compound, although the effect is not statistically significant. Compounds IV, V, and VI localize to a greater extent in the liver of tumour-free animals than in the liver of the tumourbearers (ratios 2X67, 2.57 and oo, respectively, in Table II ). The difference in the uptake of the compounds by the control and experimental liver is statistically significant only for Compound VI (0.02 < P < 0.05). The content of Compound VII in the liver of both groups of animals is similar (ratio 0.93). In the spleen of tumour-free rats 1-5 times more Compound VII is found than in the presence of tumour (0.05 < P < 0.1), and also larger amounts of Compounds V and VI are found in this organ of the control group than in the tumour-bearers (the differences between the two groups for Compounds V and VI are not, however, significant). Thus, in general, the four disulphonamides (Compounds IV, V, VI and VII) tend to follow the behaviour of the pattern compound: N,N'-bis(naphthalene)-2,7-fluorene[35S]disulphonamide with which an impaired function of the reticuloendothelial system in the presence of tumour has been shown (Argus, 1961; Argus, Hudson, Seepe, Kane and Ray, 1962) .
The aspect of a possible diagnostic value of recently obtained disulphonamides can be discussed only in relation to Compounds IV, VI and VII for which radioactivity is found in tumour 6 hours after their intravenous injections into experimental rats. In Table III the ratios of the concentration of radioactivity in tumour to the concentration in other tissues for the three disulphonamides and also for Compound I (Malejka, 1965) are presented.
As has been pointed out, the distributions of Compounds IV and VI appear to be very similar as are also the values of their concentrations in tumour. For (Malejka, 1965) . It has been shown bv means of radioelectrophoresis that the latter compound is strongly attached to rat and human serum albumins (Malejka, Kasprzak and Radola, 1966 Table III for red blood cells (8.50 at P < 0.001). blood plasma (1.89 at P--0-05), lungs (1.57 at 041 < P < 0.2), leg muscle (10.9 at P -0.02) and carcass (2-65 at P < 0.001). synthesized, and their tissue distribution 6 hours after a single intravenous injection to tumour-bearing (Walker carcinosarcoma) and tumour-free Wistar rats was studied. The data obtained are discussed in relation to the bis-thiazole (Compound I) and bis-guanidyl (Compound II) derivatives examined previously (Malejka. 1965 
